140 related articles for article (PubMed ID: 38334173)
21. Biochemistry and clinical relevance of lipoprotein X.
Narayanan S
Ann Clin Lab Sci; 1984; 14(5):371-4. PubMed ID: 6476782
[TBL] [Abstract][Full Text] [Related]
22. [Effect of biliary obstruction on lipoprotein(a) concentration].
Calmarza P; Bajador E; Lapresta C; García Castañón S; de Castro I; Civeira F
Clin Investig Arterioscler; 2014; 26(5):218-23. PubMed ID: 24629889
[TBL] [Abstract][Full Text] [Related]
23. [Lipoprotein X (LP-X) in the differential diagnosis of cholestasis in children, with special reference to biliary atresia].
Duchnowska A; Wach K; Poradowska W
Probl Med Wieku Rozwoj; 1979; 8():84-91. PubMed ID: 263531
[TBL] [Abstract][Full Text] [Related]
24. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
25. How to optimize lipoprotein apheresis treatment--a second look.
Schettler V; Neumann CL; Hagenah GC; Schulz EG; Wieland E
Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
[TBL] [Abstract][Full Text] [Related]
26. A High-Throughput NMR Method for Lipoprotein-X Quantification.
Garcia E; Shalaurova I; Matyus SP; Freeman LA; Neufeld EB; Sampson ML; Zubirán R; Wolska A; Remaley AT; Otvos JD; Connelly MA
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338310
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein-X.
Narayanan S
CRC Crit Rev Clin Lab Sci; 1979 Aug; 11(1):31-51. PubMed ID: 389551
[TBL] [Abstract][Full Text] [Related]
28. Controversy over the atherogenicity of lipoprotein-X.
Miida T; Hirayama S
Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):117-123. PubMed ID: 30694826
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
30. Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis.
Heimerl S; Boettcher A; Kaul H; Liebisch G
Biochim Biophys Acta; 2016 Aug; 1861(8 Pt A):681-7. PubMed ID: 27112638
[TBL] [Abstract][Full Text] [Related]
31. Impact of therapeutic plasma exchange on cyclosporine kinetics during membrane-based lipid apheresis.
Balogun RA; Sahadevan M; Sevigny J; Kaplan AA
Am J Kidney Dis; 2001 Jun; 37(6):1286-9. PubMed ID: 11382700
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
Edwards CM; Otal MP; Stacpoole PW
Metabolism; 1993 Jul; 42(7):807-13. PubMed ID: 8345791
[TBL] [Abstract][Full Text] [Related]
33. Dyslipoproteinaemia of liver disease.
Miller JP
Baillieres Clin Endocrinol Metab; 1990 Dec; 4(4):807-32. PubMed ID: 2082907
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
[TBL] [Abstract][Full Text] [Related]
35. PSEUDOHYPONATREMIA IN THE SETTING OF HYPERCHOLESTEROLEMIA.
El Hage L; Reineks E; Nasr C
AACE Clin Case Rep; 2019; 5(2):e172-e174. PubMed ID: 31967027
[TBL] [Abstract][Full Text] [Related]
36. Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver.
Zidan H; Lo S; Wiebe D; Talano J; Alemzadeh R
Pediatr Blood Cancer; 2008 Jun; 50(6):1280-1. PubMed ID: 18286546
[TBL] [Abstract][Full Text] [Related]
37. [The significance of LP-X cholesterol in the differential diagnosis of cholestasis (author's transl)].
Wieland H; Meissner-Heins H; Heins C; Seidel D
Klin Wochenschr; 1982 Apr; 60(7):343-8. PubMed ID: 7078029
[TBL] [Abstract][Full Text] [Related]
38. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma.
Hubscher SG; Lumley MA; Elias E
Hepatology; 1993 Jan; 17(1):70-7. PubMed ID: 7678577
[TBL] [Abstract][Full Text] [Related]
39. Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients.
Baldassarre D; Tremoli E; Franceschini G; Michelagnoli S; Sirtori CR
Stroke; 1996 Jun; 27(6):1044-9. PubMed ID: 8650712
[TBL] [Abstract][Full Text] [Related]
40. Vanishing bile duct syndrome: a rare cause of jaundice in Hodgkin's lymphoma.
Amer S; Muqeetadnan M; Rahman A; Nusrat S; Hassan S
Turk J Gastroenterol; 2013; 24(5):444-6. PubMed ID: 24557970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
